Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-peptide
- Development stage
- Preclinical
- Lead developer
- Linqmed
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
64Cu-peptide is a preclinical-stage radiolabeled peptide diagnostic agent being developed by Linqmed for the detection and localization of neuroendocrine tumors. The agent utilizes the copper-64 (64Cu) radioisotope, which emits positrons suitable for high-resolution positron emission tomography (PET) imaging. By conjugating 64Cu to a tumor-targeting peptide, the diagnostic tracer is designed to selectively bind to receptors overexpressed on neuroendocrine tumor cells, enabling non-invasive visualization of the disease.
02
Targets
DNA
Beyond the preview
Go deeper on 64Cu-peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-peptide.